Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-omics clinical study of recombinant zoster vaccine (CHO cell) immune protection mechanisms
CTR20244020Phase 2Active
- Sponsor
- Beijing Luzhu Biotechnology
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Zoster vaccine recombinant in herpes zoster (HZ), Varicella zoster infection, sponsored by Beijing Luzhu Biotechnology. Started Oct 2024; status: active.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)Varicella zoster infection
Beyond the preview
Go deeper on CTR20244020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244020.